VANCOUVER, British Columbia, Feb. 18, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Adam Rogers, MD, President and Chief Executive Officer of NervGen, and other members of the Company’s executive leadership team, are scheduled to participate at multiple ...

VANCOUVER, British Columbia, Feb. 12, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced that Bill Adams will retire as Chief Financial Officer, effective March 15th, 2026. The Company has engaged a leading executive search firm to identify a successor, and Mr. Ad ...

Adam Rogers, MD, President and Chief Executive Officer of NervGen to present and discuss clinical data from the Phase 1b/2a CONNECT SCI Study demonstrating durable improvement in function, independence, and quality of life in chronic spinal cord injury VANCOUVER, British Columbia, Feb. 11, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord inj ...

VANCOUVER, British Columbia, Feb. 09, 2026 (GLOBE NEWSWIRE) -- NervGen Pharma Corp. (“NervGen” or the “Company") (TSXV: NGEN) (NASDAQ: NGEN), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions, today announced its Board of Directors has unanimously appointed Adam Rogers, MD, as President and Chief Executive Officer (CEO), effective immediately. Dr. Rogers will continue leading the C ...

Core Viewpoint - NervGen Pharma Corp. has appointed Dr. Adam Rogers as President and CEO, reflecting the Board's confidence in his leadership and vision for the company's future in neuroreparative therapeutics for spinal cord injury [1][2][3] Company Leadership - Dr. Rogers has been recognized for his decisive execution during his tenure as Interim CEO, including the successful Nasdaq listing and positioning of NVG-291 for late-stage development [2][3] - The Board believes Dr. Rogers embodies the leadership qualities necessary for advancing novel therapies, emphasizing his background as a physician and biotech executive [3] Company Mission and Product Development - NervGen's mission is to transform the lives of individuals with spinal cord injuries by enabling the nervous system to repair itself [6][7] - The lead therapeutic candidate, NVG-291, has shown durable improvement in function and quality of life in clinical studies and is preparing for a Phase 3 trial [7] - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the EMA, highlighting its potential in addressing significant unmet medical needs [7] Stock Options and Compensation - In connection with Dr. Rogers' appointment, the company granted 717,891 stock options, with specific vesting schedules and exercise prices [3]

Core Viewpoint - NervGen Pharma Corp. is set to ring the closing bell at the Nasdaq Stock Market on January 22, 2026, marking a significant milestone in the company's growth and evolution as a clinical-stage biopharmaceutical company focused on neuroreparative therapeutics for spinal cord injury and other neurological conditions [1][3]. Company Overview - NervGen Pharma Corp. is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics aimed at transforming the lives of individuals with spinal cord injury (SCI) by enabling the nervous system to repair itself [4]. - The company's lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide that has shown durable improvement in function, independence, and quality of life in individuals with chronic SCI [4]. - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency (EMA) for the treatment of SCI, with ongoing enrollment in a Phase 1b/2a clinical study and preparations for a Phase 3 trial [4]. Leadership and Recognition - Adam Rogers, MD, Chairman and Interim Chief Executive Officer, emphasized the honor of participating in the Nasdaq closing bell ceremony and acknowledged the support from shareholders, collaborators, and families involved in clinical research [3]. - The event will be livestreamed from the Nasdaq MarketSite Tower, showcasing the company's mission and achievements to a broader audience [3].

Core Viewpoint - NervGen Pharma Corp. has received approval for its common shares to be listed on Nasdaq, marking a significant milestone in its development as a biopharmaceutical company focused on neuroreparative therapeutics for spinal cord injury and other neurological conditions [1] Company Overview - NervGen Pharma is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics aimed at transforming the lives of individuals with spinal cord injury (SCI) [2] - The lead therapeutic candidate, NVG-291, is a subcutaneously administered neuroreparative peptide that has shown durable improvements in function, independence, and quality of life in chronic SCI patients [2] - NVG-291 has received Fast Track designation from the FDA and Orphan Drug designation from the European Medicines Agency for the treatment of SCI [2] Recent Developments - The listing on Nasdaq is expected to enhance market visibility, improve liquidity, and broaden the shareholder base, ultimately driving long-term shareholder value as the company advances NVG-291 [1] - Recent Phase 1b/2a CONNECT SCI Study data revealed unprecedented durable improvements in function and quality of life for individuals with chronic SCI, with significant enhancements in upper-limb corticospinal signaling [1] - The company plans to conduct a U.S. FDA End-of-Phase 2 meeting in early 2026 to discuss the development and registration pathway for NVG-291 [1]

Core Viewpoint - NervGen Pharma Corp. is amending the exercise price of its 2022 Warrants from US$1.75 to the Canadian equivalent of C$2.44 to align with its functional currency and simplify accounting treatment, while all other terms remain unchanged [1] Company Overview - NervGen Pharma Corp. is a clinical-stage biopharmaceutical company focused on developing neuroreparative therapeutics for spinal cord injury and other neurological disorders [1][3] - The company is evaluating its lead candidate, NVG-291, in the Phase 1b/2a CONNECT SCI Study for spinal cord injury [3] Product Information - NVG-291 is a first- and potential best-in-class therapeutic peptide that enables the nervous system to repair itself, with exclusive worldwide rights held by NervGen [2] - The technology for NVG-291 is licensed from Case Western Reserve University, based on studies showing its preclinical efficacy in promoting neurorepair and functional improvement in spinal cord injury models [2] - NVG-291 has received Fast Track designation from the FDA and Orphan Designation from the EMA for spinal cord injury [2]

Core Insights - NervGen Pharma Corp. reported significant progress in its second quarter 2025 financial results, highlighting the groundbreaking topline results from the CONNECT SCI Study, which demonstrated that NVG-291 treatment significantly improved corticospinal connectivity and restored meaningful function for individuals with chronic spinal cord injury [5][10] Financial Results - As of June 30, 2025, the company had cash and investments totaling $15.7 million, a decrease from $17.3 million as of December 31, 2024, primarily due to operating activities related to the CONNECT SCI Study [20] - Research and Development (R&D) expenses for the quarter were $2.7 million, down from $3.8 million in the same period in 2024, attributed to lower clinical and regulatory costs [21] - General and Administrative (G&A) expenses increased to $3.8 million from $2.2 million year-over-year, mainly due to higher compensation-related expenses and external legal costs [22] - The net loss for the quarter was $9.1 million, or $0.13 per share, compared to a net loss of $7.8 million, or $0.11 per share, in the same quarter of 2024 [23] Clinical Development - The CONNECT SCI Study marked a historic turning point, with NVG-291 being the first pharmacologic candidate to show statistically significant improvement in corticospinal connectivity and clinically meaningful functional gains in chronic spinal cord injury [8][15] - The study reported a 10.2-fold improvement in observed mean change from baseline in motor evoked potential (MEP) magnitude compared to placebo, indicating significant efficacy [16] - NVG-291 demonstrated a favorable safety profile, being generally safe and well tolerated without treatment-emergent adverse events leading to discontinuation [19] Pipeline Progress - The company is conducting a comprehensive analysis of NVG-291's efficacy profile, which will inform upcoming regulatory discussions with the FDA regarding potential expedited approval pathways [12][9] - Positive preclinical results were announced for NVG-291-R in models of traumatic hearing loss and peripheral nerve injury, showing significant functional recovery [13][14] Corporate Developments - In July 2025, NervGen transitioned its senior leadership, appointing Adam Rogers, MD, as Interim CEO and Randall Kaye, MD, as Chief Medical Advisor to ensure continuity in the company's mission [20][26] - The company holds exclusive worldwide rights to NVG-291, which is based on research from Case Western Reserve University and has received Fast Track designation from the FDA and Orphan Designation from the EMA for spinal cord injury [27][28]

NervGen Pharma's NVG-291-R Demonstrates Significant Functional Recovery in Department of Defense-Sponsored Preclinical Models of Traumatic Hearing Loss and Peripheral Nerve Injury August 21, 2025 7:30 AM EDT | Source: NervGen Pharma Corp. Vancouver, British Columbia--(Newsfile Corp. - August 21, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other neurologic disorders, toda ...